Adlai Nortye Biopharma Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Adlai Nortye Biopharma Co. sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Adlai Nortye Biopharma Co.: 6 sponsored US clinical trials, 2 recruiting.
Adlai Nortye Biopharma Co. sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neoadjuvant Therapy in Rectal Cancer, with 1 trials.
Upper-quartile sponsor footprint
Adlai Nortye Biopharma Co. sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
NCT07252479
First in Human, Dose Escalation Study of AN4005
NCT04999384
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
NCT04432857
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
NCT04975958
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
NCT04338399
Preoperative Radiotherapy and E7046 in Rectum Cancer
NCT03152370
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Adlai Nortye Biopharma Co. pipeline
2 recruiting of 6 indexed (33% open); 3 completed (50%).
Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Neoadjuvant Therapy in Rectal Cancer (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Adlai Nortye Biopharma Co.: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Adlai Nortye Biopharma Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Adlai Nortye Biopharma Co. page
6 registered trials is a research-attention snapshot, not an endorsement of Adlai Nortye Biopharma Co. or any single study.
- 2 of Adlai Nortye Biopharma Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Neoadjuvant Therapy in Rectal Cancer is the condition Adlai Nortye Biopharma Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neoadjuvant Therapy in Rectal Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Adlai Nortye Biopharma Co. pipeline card: 6 registered trials from official public datasets.Report a data error.